Table I.
Plasma Pharmacokinetics of Non-Liposomal Irinotecan and Liposomal Irinotecan
| Treatment | AUC0-α (ng-hr/mL) × 105 | t1/2 (h) | MRT (h) | Cl (ml/h) | Vd (ml) |
|---|---|---|---|---|---|
| Plasma Irinotecan | |||||
| IRI-50 | 0.2 ± 0.02 | 3.3 ± 0.1 | 2 ± 0.5 | 85.7 ± 22.8 | 178.6 ± 64.7 |
| na-IRI-10 | 3.2± 0.9 | 12.7 ± 0.5 | 4.5 ± 0.4 | 0.6 ± 0.2 | 2.9 ± 0.5 |
| na-IRI-50 | 45 ± 5.5 | 10.9 ± 0.3 | 7.3 ± 2.6 | 0.3 ± 0.1 | 2.2 ± 1.1 |
| Treatment | AUC0-α (ng-hr/mL) × 103 | t1/2 (h) | MRT (h) | Cl (ml/h) | Vd (ml) |
| Plasma SN-38 | |||||
| IRI-50 | 0.6 ± 0.08 | 4.32 ± 3.2 | 3.67 ± 1.2 | 2472 ± 881 | 7845.6 ± 2023 |
| na-IRI-10 | 2.6 ±0.6 | 21 ± 2.9 | 16.7 ± 8.3 | 80.9 ± 13.5 | 1327.5 ± 678 |
| nal-IRI-50 | 9.7 ± 0.4 | 18 ± 1.3 | 17.7 ± 3.8 | 130.2 ± 11.9 | 1990.3 ± 329 |
AUC0-α Area under the time-concentration cure, Cl Clearance, MRT Mean residence time, t1/2 plasma half-life of the drug, Vd Apparent volume of distribution